Lonza has unveiled a new organizational structure and strategy that focuses on its core CDMO business, which includes shedding its Capsules & Health Ingredients business.
Lonza said it plans to exit the capsules space “at the appropriate time and in the best interest of shareholders and stakeholders,” and will outline next steps in 2025.
The organizational structure for the CDMO business will evolve from three divisions with nine underlying business units, to a simplified ‘One Lonza’ set-up with three integrated business platforms: Integrated Biologics, Advanced Synthesis and Specialized Modalities. Integrated Biologics will include mammalian and drug product services; Advanced Synthesis will comprise the former small molecules division and bioconjugates; and Specialized Modalities will include cell and gene technologies, mRNA, microbial and bioscience.
The news was shared during an investor update by Lonza CEO Wolfgang Wienand, who took the helm this past July.
“Today, we have shared the plans for our One Lonza strategy, propelled by the Lonza Engine, and a revised organizational structure which will support our ambition to create long-term value for our customers and our shareholders. The strategy reflects our ambition to become a pure-play CDMO business. This will allow us to achieve and maintain leadership across modalities with high therapeutic and commercial value, while pioneering the manufacturing technologies of the future,” said Wienand.
The new structure will be operational from Q2 2025.